One linked filing — more sources may join as they report · filed May 26, 2025. View entity profile → Other incidents for this victim →
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
incident inc_5aa76f09ae4d4979 · merge_method deterministic
Not recorded for this incident
Discovery variance · Leak precedence · Materiality delta · SEC filing delay · Filing span — no SEC 8-K in this cluster; needs two dated filings.
all Leak Site
Earliest sighting first · deep chronology in Litigation Timeline
InnoMedica is a Swiss-based biopharmaceutical firm focused on the development of tailored treatments for serious conditions such as cancer and neurological disorders. Its primary product, Talidox, is a nanomedical cancer drug that targets only tumor cells. InnoMedica's research is focused towards the technological advancements in medicine to provide more effective treatments.
About this clustering
DisclosureLens links filings into incidents through layered matchers: deterministic rules (same source document, multistate filings of one breach, tight-window same-victim pairs), a weighted-similarity scorer for cross-source candidates, and an operator review queue for everything uncertain. Each link records its own method and confidence — shown per filing in the timeline below. The system defaults to NOT merging when uncertain, because a false merge (collapsing two unrelated breaches) is more harmful than a false split (showing related filings separately); uncertain pairs route to human review instead of auto-merging. Filing summaries shown in the timeline are AI-generated extracts — verify each against its linked source.